Attached files

file filename
EX-99.2 - PRO FORMA FINANCIAL INFORMATION LISTED IN ITEM 9.01(B) - Adamis Pharmaceuticals Corpex99-2.htm
EX-99.1 - FINANCIAL STATEMENTS LISTED IN ITEM 9.01(A) - Adamis Pharmaceuticals Corpex99-1.htm
8-K/A - AMENDED CURRENT REPORT - Adamis Pharmaceuticals Corpadmp-8k_041116.htm
 

Adamis Pharmaceuticals Corporation 8-K/A

 

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We hereby consent to the incorporation by reference in the Prospectuses constituting a part of the Registration Statements of Adamis Pharmaceuticals Corporation on Form S-8 (Nos. 333-159229, 333-169106, 333-175383, 333-196435, and 333-201742), on Form S-1 (Nos. 333-190798, 333-192372, and 333- 192801), and on Form S-3 (Nos. 333-196976, 333-199454, 333-200447 and 333-209401), of our report dated March 23, 2016 (which includes an explanatory paragraph relating to the uncertainty of the company’s ability to continue as a going concern), relating to the financial statements of U.S. Compounding, Inc. as of and for the periods ended December 31, 2015 and December 31, 2014, which report is included in the Current Report on Form 8-K/A of Adamis Pharmaceuticals Corporation filed with the Securities and Exchange Commission on June 24, 2016.

 

 

/s/ HUDSON CISNE & CO. LLP

 

Little Rock, Arkansas

June 24, 2016